Monoclonal Antibodies for Waldenström Macroglobulinemia.

Abstract

For the last 2 decades, anti-CD20 monoclonal antibodies have revolutionized the treatment of patients with B-cell lymphomas. These agents have shown efficacy when used as single agents and also have improved response and survival rates when added to chemotherapy. Monoclonal antibodies are safe and effective as well in patients with Waldenström macroglobulinemia (WM). The purpose of this article is to review the mechanism of action of monoclonal antibodies and to discuss current clinical data supporting their use in patients with WM. This review focuses on retrospective and prospective studies and clinical trials on anti-CD20 antibodies, anti-CD38 antibody, and anti-CXCR4 antibody.

• Authors: Andres Dominguez, Efstathios Kastritis, Jorge J Castillo
• Journal: Hematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 32 Issue 5 Pg. 841-852 (Oct 2018) ISSN: 1558-1977 [Electronic] United States
• PMID: 30190022 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents, Immunological

Topics

• Antineoplastic Agents, Immunological (immunology, therapeutic use)
• Humans
• Waldenstrom Macroglobulinemia (drug therapy, immunology, pathology)